Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Co-Administered CHI-554 (CBD) and Alcohol
NCT05317507Phase 1Completed
- Sponsor
- Auburn University
- Start
- May 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CHI-554 (6 arms), sponsored by Auburn University. Primary endpoints: Adverse Events and Serious Adverse Events at Day 34, Change from baseline in Alanine aminotransferase at Day 34 and 1 more. Started May 2022; status: completed.
02
Drugs
CHI-554
Beyond the preview
Go deeper on NCT05317507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317507.